Press coverage about Biocept (NASDAQ:BIOC) has been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biocept earned a daily sentiment score of 0.31 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Biocept (BIOC) vs. TrovaGene (TROV) Head to Head Survey (americanbankingnews.com)
- Biocept, Inc. (NASDAQ:BIOC) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Unusual Activity Spotted in Biocept Inc (BIOC) – Stock Press Daily (stockpressdaily.com)
- Shares Running on Volume: Biocept Inc (BIOC) – Wall Street Review (thewallstreetreview.com)
- K2M Group Holdings, Inc. (KTWO) is at $25.71 per share and Biocept, Inc. (BIOC) is listed at $1.41 – Stocks Gallery (stocksgallery.com)
Biocept (BIOC) traded up 3.73% during midday trading on Friday, hitting $1.39. 228,112 shares of the stock traded hands. The stock’s market cap is $36.97 million. The company has a 50-day moving average of $1.40 and a 200-day moving average of $1.72. Biocept has a 1-year low of $0.74 and a 1-year high of $3.39.
A number of brokerages have commented on BIOC. ValuEngine upgraded shares of Biocept from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Zacks Investment Research lowered shares of Biocept from a “buy” rating to a “hold” rating in a report on Thursday, June 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $2.31.
TRADEMARK VIOLATION NOTICE: “Biocept (BIOC) Earning Favorable Press Coverage, Analysis Shows” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/30/biocept-bioc-receives-daily-media-sentiment-rating-of-0-31-updated-updated-updated.html.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with MarketBeat.com's FREE daily email newsletter.